New 6-Month TB drug combo tested in diabetic patients

NCT ID NCT07191834

Not yet recruiting Disease control Sponsor: Wuhan Pulmonary Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a 6-month treatment regimen containing pretomanid for people with drug-resistant tuberculosis who also have type 2 diabetes. Researchers will compare how well the treatment works and how safe it is in diabetic patients versus non-diabetic patients. The goal is to see if this shorter, all-oral regimen is a good option for this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pretomanid (combined with bedaquiline, linezolid, and moxifloxacin)
What this could lead to: If successful, this could show that a shorter, all-oral treatment works safely for people with both drug-resistant TB and diabetes, improving cure rates and reducing side effects.
What could go wrong: This is a small, early-stage study with only 60 participants, and results may not apply to all patients. People with diabetes may still experience more side effects or lower cure rates than expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multidrug-resistant tuberculosis rifampicin-resistant tuberculosis type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRETOMANID RIFAMPICIN-RESISTANT/MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS TYPE 2 DIABETES MELLITUS (T2DM)

More trials for these conditions

Other studies related to the condition(s) this trial covers.